Sponsors
Blog
Where our team of editors discuss what they think about the current NGP US Issues.
Editor NGP Europe
Tough competition
The battle between generics and branded products has been going on for a long time: the claims and counter claims over Aspirin, for example, have been in process since the early 20th century.05 Aug 2009
Focus Area: Drug Discovery
The L-Factor: "We’ve got the critical mass”
Franz Humer, a lawyer by training, is CEO of F. Hoffmann-La Roche Ltd – a company whose strategy is to use innovative scientific breakthroughs to shape the future of medicine.
Great expectations
The pharmaceutical business – once the envy of fellow industries for its year-on-year surging profits – has suddenly found itself staring at a crisis.
The EU and you
Martin Terberger, Head of Unit, Pharmaceuticals, Directorate General, Enterprise and Industry outlines the European Commission’s view on pharma moving forward.
It’s all about… Innovation
In their quest to be innovative, pharmaceutical and biotechnological companies are applying their own strategies in response to the growing demands for improvement, creative ideas, breakthrough technologies and new medicines.
European pharma: where next?
What does Europe have to gain from an innovative, research-based pharmaceutical industry? And what challenges is the industry facing? By Brian Ager, Director General of the European Federation of Pharmaceutical Industries and Associations EFPIA.
Source: www.ngpharma.eu.com© 2010 GDS Publishing Ltd. All rights reserved.